UTv Videos

“Where I have found that it has been incredibly useful has been in those unfavorable intermediate-risk patients or those individuals who are kind of borderline at the risk spectrum,” says Rana R. McKay, MD.

“The purpose of the course is really to bring together like-minded surgeons and physicians who are interested in robotic reconstructive surgery to really come together to not only build a network, but also discuss complex situations, discuss tips and tricks, and also to review the most salient literature in this space,” says Ziho Lee, MD.

"Given that these lesions are common, even if surgeons aren't treating adrenal tumors, they're certainly going to find some on imaging," says Neal E. Rowe, MD, FRCSC.

“I was of course flattered when Dr. Walsh and Janet Worthington approached me to take the lead on editing and writing this fifth version of the book,” says Edward M. Schaeffer, MD, PhD.

"It's very important to build trust early on for a urologist and with a patient so that they're more likely to stay with a screening program," says Daniel E. Spratt, MD.

Joshi Alumkal, MD, highlights findings from the phase 3 ARASENS trial that led to the FDA approval of darolutamide for use in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer.

“About 25% of men didn't even want to know that they had cancer,” says Daniel E. Spratt, MD.

"Sometimes, when you just look at people in the eye, you sort of can forget about everything else; you can just focus on that person in front of you," says Diana Londoño, MD.

“What's so great about the ArteraAI platform is the simplicity in which this test is performed,” says Rana R. McKay, MD.

“It’s exciting that now in 2023 we have 3 FDA-approved PARP inhibitors for the treatment of our prostate cancer patients,” says Joshi Alumkal, MD.

“When we are starting to do this in urology across the world, we need to make sure that we have patient representatives involved and they are there from the beginning to make sure that whatever we do in terms of an intervention is successful,” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.

Joshi Alumkal, MD, discusses the phase 3 TALAPRO-2 trial, which supported the FDA approval of the combination of talazoparib and enzalutamide for patients with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination repair gene defects.

“So far, all the studies have shown quite positive results with this approach. It's something that we can use in urology [for a lot of different issues],” says Nikita R. Bhatt, MBBS, MCh, MMed, FRCS.

In the setting of refractory urothelial carcinoma, Jue Wang, MD, says it is essential to thoroughly understand a patient's molecular profile, comorbidities, and residual side effects from prior lines of therapy.

“The recommendations are based on the current evidence, but the evidence is overall relatively weak. So, I think there's a lot of room for improvement,” says Neal E. Rowe, MD, FRCSC.

"When a patient or an imaging study identifies an incidental adrenal mass, the first upfront radiographic test is a non-contrast CT scan," says Neal E. Rowe, MD, FRCSC.

"We as a center prioritized using cisplatin and carboplatin for patients who are receiving curative intent chemotherapy," says Tian Zhang, MD.

“At its core, [the book is] a love letter to my patients. It's all the things that I didn't have time to tell them in a 15-minute office visit,” says Martha Boone, MD.

"You have to take care of those basic needs, because if not, you're not going to have the space to react differently when you're getting triggered," says Diana Londoño, MD.

“We're going to be able to treat many more patients who suffer from BPH/LUTS with these less invasive options,” says Dean S. Elterman, MD, MSc, FRCSC.

"Mentorship plays a huge role, and as someone who's interested in academics in the future, I think it's important to remember the influence that you can have on shaping young minds," says Niki Parikh, MD, MBA, MSBA.

“The world of surgery makes a person quite disciplined,” says Martha Boone, MD.

"I would say the take-home message from this study is that HoLEP uptake has nearly doubled from 2016 to 2019," says Jenny Guo, MD.

“It's a really exciting time for people who are interested in BPH/LUTS,” says Dean S. Elterman, MD, MSc, FRCSC.

"Interestingly enough, we found that PVP accounted for nearly a third of BPH surgeries back in 2016. This number drastically decreased to just 0.7% of all BPH surgeries in 2019," says Jenny Guo, MD.

"Only 25% of our respondents felt that sexual health curriculum provided an adequate fund of knowledge to address any of the sexual health concerns of patients," says Niki Parikh, MD, MBA, MSBA.

"If you've got a difference, pay attention to the size and direction. If you have a massive difference between groups in terms of outcome, but only a small difference in terms of baseline characteristics, that's worth talking about," says Andrew J. Vickers, PhD.

“Our identity is not just about a title; it's not just about that role. We are much bigger than that,” says Diana Londoño, MD.

"We had the idea of doing a scoping review of office-based BPH stents, as this is becoming a new and evolving hot topic in the area of male functional urology," Dean S. Elterman, MD, MSc, FRCSC.